Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort
Drug therapy for ovarian cancer is changing fast. New treatment with enzyme inhibitors and immunotherapy is having an effect to improve survival. However, these new therapies are most effective for those few women with ovarian cancer who have an inherited or acquired genetic mutation (about 12% of all cases).
For most patients the standard therapy for ovarian cancer after surgery is chemotherapy. Since 1992 this therapy has been commonplace and has significantly improved survival. Usually there is a three-week cycle of therapy; dense-dose treatment with a weekly cycle was introduced in 2011.
Side effects from dense-dose therapy are worse and a trial in Japan looking for benefit (JGOG3016) failed to show any advantage but it remains a preferred therapy option in some countries. This review was of 588 patients in Brazil, of whom 69 patients received dense-dose treatment. These patients had better progress free survival than women who had standard chemo. The authors speculate that non-Asian women are better able to tolerate high treatment doses and show better response.
No comments:
Post a Comment